Cara Therapeutics | CARA - Selling And Administration Expenses


Cara Therapeutics reported $2.09M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Cara Therapeutics USD 2.09M 96K Mar/2026
Cassava Sciences USD 3.89M 2.77M Mar/2026
Chugai Pharma JPY 29.04B 143M Jun/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 57M 10.71M Jun/2026
J&J USD 6.42B 381M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Pacira USD 91.81M 7.93M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
RedHill Biopharma USD 4.48M 1.52M Mar/2024
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024